Equities

Allogene Therapeutics Inc

ALLO:NSQ

Allogene Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.84
  • Today's Change-0.07 / -2.41%
  • Shares traded524.15k
  • 1 Year change-24.67%
  • Beta0.8281
Data delayed at least 15 minutes, as of Sep 20 2024 16:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy5
Outperform8
Hold5
Sell0
Strong Sell0

Share price forecast in USD

The 12 analysts offering 12 month price targets for Allogene Therapeutics Inc have a median target of 9.50, with a high estimate of 14.00 and a low estimate of 4.50. The median estimate represents a 226.46% increase from the last price of 2.91.
High381.1%14.00
Med226.5%9.50
Low54.6%4.50

Earnings history & estimates in USD

On Aug 07, 2024, Allogene Therapeutics Inc reported 2nd quarter 2024 losses of -0.35 per share. This result was in line with the consensus of the 15 analysts following the company and exceeded last year's 2nd quarter results by 33.96%.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate+6.43%
Allogene Therapeutics Inc reported annual 2023 losses of -2.09 per share on Mar 14, 2024.
Average growth rate-4.34%
More ▼

Revenue history & estimates in USD

Allogene Therapeutics, Inc. did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 52.00k.
Average growth rate-37.17%
Allogene Therapeutics, Inc. had revenues for the full year 2023 of 95.00k. This was 60.91% below the prior year's results.
Average growth rate-53.42%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.